Charles Schwab’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-375,239
| Closed | -$14.4M | – | 3688 |
|
|
2023
Q2 | $14.4M | Sell |
375,239
-2,888
| -0.8% | -$74.2K | ﹤0.01% | 1710 |
|
|
2023
Q1 | $8.75M | Sell |
378,127
-5,585
| -1% | -$133K | ﹤0.01% | 1936 |
|
|
2022
Q4 | $10.1M | Buy |
383,712
+9,225
| +2% | +$204K | ﹤0.01% | 1850 |
|
|
2022
Q3 | $7.36M | Buy |
374,487
+215,075
| +135% | +$4.31M | ﹤0.01% | 2008 |
|
|
2022
Q2 | $2.79M | Buy |
159,412
+47,937
| +43% | +$752K | ﹤0.01% | 2449 |
|
|
2022
Q1 | $1.82M | Buy |
111,475
+9,374
| +9% | +$127K | ﹤0.01% | 2675 |
|
|
2021
Q4 | $1.67M | Buy |
102,101
+17,501
| +21% | +$249K | ﹤0.01% | 2758 |
|
|
2021
Q3 | $1.08M | Buy |
84,600
+4,609
| +6% | +$60.7K | ﹤0.01% | 2849 |
|
|
2021
Q2 | $1.13M | Buy |
79,991
+38,774
| +94% | +$620K | ﹤0.01% | 2888 |
|
|
2021
Q1 | $641K | Buy |
41,217
+19
| +0% | +$310 | ﹤0.01% | 3004 |
|
|
2020
Q4 | $654K | Buy |
41,198
+7,583
| +23% | +$114K | ﹤0.01% | 2902 |
|
|
2020
Q3 | $409K | Sell |
33,615
-1,412
| -4% | -$18.9K | ﹤0.01% | 2937 |
|
|
2020
Q2 | $405K | Buy |
35,027
+7,386
| +27% | +$102K | ﹤0.01% | 2914 |
|
|
2020
Q1 | $379K | Sell |
27,641
-2,293
| -8% | -$27.1K | ﹤0.01% | 2804 |
|
|
2019
Q4 | $177K | Buy |
29,934
+3,854
| +15% | +$20.9K | ﹤0.01% | 3054 |
|
|
2019
Q3 | $139K | Sell |
26,080
-35,136
| -57% | -$233K | ﹤0.01% | 3078 |
|
|
2019
Q2 | $472K | Buy |
61,216
+2,233
| +4% | +$34K | ﹤0.01% | 2837 |
|
|
2019
Q1 | $1.17M | Buy |
58,983
+3,635
| +7% | +$63.4K | ﹤0.01% | 2514 |
|
|
2018
Q4 | $731K | Sell |
55,348
-3,667
| -6% | -$73.3K | ﹤0.01% | 2635 |
|
|
2018
Q3 | $2.17M | Buy |
59,015
+12,345
| +26% | +$396K | ﹤0.01% | 2406 |
|
|
2018
Q2 | $1.63M | Buy |
46,670
+13,856
| +42% | +$531K | ﹤0.01% | 2434 |
|
|
2018
Q1 | $1.53M | Buy |
32,814
+2,972
| +10% | +$109K | ﹤0.01% | 2412 |
|
|
2017
Q4 | $1.12M | Sell |
29,842
-5,054
| -14% | -$221K | ﹤0.01% | 2477 |
|
|
2017
Q3 | $1.86M | Buy |
34,896
+1,828
| +6% | +$109K | ﹤0.01% | 2317 |
|
|
2017
Q2 | $1.89M | Buy |
33,068
+4,046
| +14% | +$203K | ﹤0.01% | 2242 |
|
|
2017
Q1 | $1.56M | Buy |
29,022
+1,562
| +6% | +$88.2K | ﹤0.01% | 2281 |
|
|
2016
Q4 | $1.57M | Buy |
27,460
+1,469
| +6% | +$88.9K | ﹤0.01% | 2276 |
|
|
2016
Q3 | $1.62M | Buy |
25,991
+12,877
| +98% | +$910K | ﹤0.01% | 2237 |
|
|
2016
Q2 | $742K | Buy |
13,114
+8,727
| +199% | +$530K | ﹤0.01% | 2449 |
|
|
2016
Q1 | $281K | Buy |
4,387
+82
| +2% | +$6.63K | ﹤0.01% | 2797 |
|
|
2015
Q4 | $606K | Buy |
4,305
+104
| +2% | +$14.1K | ﹤0.01% | 2561 |
|
|
2015
Q3 | $407K | Buy |
4,201
+266
| +7% | +$31.7K | ﹤0.01% | 2702 |
|
|
2015
Q2 | $597K | Buy |
+3,935
| New | +$650K | ﹤0.01% | 2617 |
|
Charles Schwab's KDNY Position: Q3 2023 in Review
Charles Schwab sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 375,239 shares — an estimated $14.4M sold.
Charles Schwab first reported a position in KDNY in Q2 2015 and held it in 33 quarters. The position peaked at $14.4M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Charles Schwab reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Charles Schwab sold 375,239 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $14.4M.
- Charles Schwab first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 33 quarters.
- Charles Schwab's Chinook Therapeutics, Inc. Common Stock position peaked at $14.4M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Charles Schwab's 13F filing for Q3 2023, filed 8 Nov 2023.